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Abstract 
Objective: To determine the expression of autistic and positive schizotypal traits in a large 
sample of adults with bipolar I disorder (BD-I), and the effect of co-occurring autistic and 
positive schizotypal traits on global functioning in BD-I. Method: Autistic and positive 
schizotypal traits were self-assessed in 797 individuals with BD-I recruited by the Bipolar 
Disorder Research Network. Differences in global functioning (rated using the Global 
Assessment Scale) during lifetime worst depressive and manic episodes (GASD and GASM 
respectively) were calculated in groups with high/low autistic and positive schizotypal traits. 
Regression analyses assessed the interactive effect of autistic and positive schizotypal traits 
on global functioning. Results: 47.2% (CI=43.7-50.7%) showed clinically significant levels of 
autistic traits, and 23.22% (95% CI=20.29-26.14) showed clinically significant levels of 
positive schizotypal traits. In the worst episode of mania, the high autistic, high positive 
schizotypal group had better global functioning compared to the other groups. Individual 
differences analyses showed that high levels of co-occurring traits were associated with 
better global functioning in both mood states. Limitations: Autistic and schizotypal traits 
were assessed using self-rated questionnaires. Conclusions: Expression of autistic and 
schizotypal traits in adults with BD-I is prevalent, and may be important to predict illness 
aetiology, prognosis, and diagnostic practices in this population. Future work should focus 
on replicating these findings in independent samples, and on the biological and/or 
psychosocial mechanisms underlying better global functioning in those who have high levels 
of both autistic and positive schizotypal traits. 
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Introduction 
Bipolar disorder (BD) is a major affective disorder characterised by chronically recurring 
episodes of mania (or hypomania) and depression, which in their severe forms may present 
with psychotic symptoms, such as hallucinations or delusions (Weissman et al., 1996). This 
complex condition is often exacerbated by the presence of one or more comorbid 
conditions, in addition to a number of clinical factors such long duration of illness (Altamura 
et al., 2015; Altamura et al., 2010). While BD, schizophrenia spectrum disorders (SSD) and 
autism spectrum disorders (ASD) are considered distinct conditions, there is evidence for an 
overlap between BD and SSD (Altamura, Buoli, & Pozzoli, 2014; Carroll & Owen, 2009; 
Moller, 2003), as well as between ASD and BD (Carroll & Owen, 2009; Stahlberg, 
Soderstrom, Rastam, & Gillberg, 2004). Indeed, BD has a number of genetic, 
symptomatological and epidemiological overlaps with SSD (Laursen, Agerbo, & Pedersen, 
2009; Lichtenstein et al., 2009; Murray et al., 2004), and psychosis has been recognised as 
an important dimension in the psychopathology of BD (van Os & Kapur, 2009). In addition, 
schizotypy, which encompasses a set of personality traits that reflect subclinical expression 
of schizophrenia (Ettinger et al., 2015), is recognised as genetically related to SSD and is 
considered an endophenotype common to both SSD and BD (Ettinger, Meyhofer, Steffens, 
Wagner, & Koutsouleris, 2014; Mahon, Perez-Rodriguez, Gunawardane, & Burdick, 2013; 
Schurhoff, Laguerre, Szoke, Meary, & Leboyer, 2005). Schizotypy has been reported at 
elevated rates in individuals with BD compared to healthy controls, although this was 
conducted in a relatively small BD sample (N=92) (Heron et al., 2003).  
 
Furthermore, there is growing evidence of an association between ASD and BD (Cross-
Disorder Group of the Psychiatric Genomics, 2013; Vannucchi et al., 2014). ASD is defined by 
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its cardinal impairments in social interaction, language and communication, and restricted 
behaviour and interests. To date, the majority of reports of ASD-BD comorbidity are in ASD 
samples, with prevalences ranging from 6% to 21.4% (Vannucchi et al., 2014). Only two 
studies have assessed ASD in BD samples: in youths (aged 7-17 years, N=157), 30% met 
diagnostic criteria for ASD (Joshi et al., 2013); and in a small sample of adults (N=56), 50% 
had high levels of autistic traits as measured with the Social Responsiveness Scale (Matsuo 
et al., 2015). Thus the extant literature reporting the expression of autistic or schizotypal 
traits in BD has been limited by small samples, and requires replication in large, well-
characterised, adult samples of BD.  
 
The interplay between BD, SSD and ASD or expression of their traits may have significant 
consequences on global functioning in patients with BD. Global functioning, a measure of 
illness severity, provides an overall picture of an individual’s combined psychological, social 
and occupational functioning, such as how adaptive the patient is in dealing with social and 
interpersonal problems (Endicott, Spitzer, Fleiss, & Cohen, 1976). Poor functioning has been 
reported in individuals with schizotypal personality disorder (Henry, Bailey, & Rendell, 2008; 
Skodol et al., 2002), schizophrenia (Robertson et al., 2013) and ASD (Engstrom, Ekstrom, & 
Emilsson, 2003; Kastner et al., 2015). Hence a combined worsening effect may be expected 
in BD patients with high levels of co-occurring autistic and schizotypal traits. A recent study 
evaluated the effect of co-occurring autistic and positive schizotypal (i.e. relating to 
psychotic-like experiences) traits on the ability to appreciate the perspective of others (or 
mentalising) in the general population (N=201) (Abu-Akel, Wood, Hansen, & Apperly, 2015). 
It showed that while autistic and positive schizotypal traits independently induced 
perspective-taking errors, their interaction was associated with fewer errors, reflecting an 
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improvement in mentalising abilities. The authors proposed that this unexpected finding 
may be explained by the diametric model (Crespi & Badcock, 2008), which postulates that 
ASD and SSD have opposing effects on mentalising abilities, whereby autism is associated 
with reduced or no mentalising, and schizophrenia with dysfunctional overmentalising. 
While global functioning is not a test of mentalising per se, it has been shown to be 
associated with socio-cognitive abilities (Bo, Kongerslev, Dimaggio, Lysaker, & Abu-Akel, 
2015) and improve following mentalising-based treatments (Bateman & Fonagy, 2008). To-
date, no study has investigated the effect of co-occurring autistic and schizotypal traits on 
an outcome of clinical value in a psychiatric population. 
 
Thus the present study has two main objectives: (1) to determine the expression of autistic 
and positive schizotypal traits in a large sample of adults with BD, and (2) to examine 
whether co-occurring autistic and positive schizotypal traits interact to affect global 
functioning in this population. The assessment of positive schizotypy only, rather than the 
general construct of schizotypy (comprising both positive and negative traits), is based on 
evidence that autistic and schizotypal traits cannot be distinguished by the presence or 
absence of negative traits, due to similarities in impaired social and communicative 
functioning (Spek & Wouters, 2010). Moreover, given that ASD is more prevalent in males 
compared to females (Lehnhardt et al., 2016), the expression of autism traits in our sample 
were analysed for male and female patients separately.  
 
Investigating the prevalence of autistic and schizotypal traits in BD has management 
implications for individuals with BD, and may contribute to understanding the aetiology of 
BD. Moreover, isolating and characterising the expression of autistic and schizotypal traits is 
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important to understanding the nature of their effect on the course, outcome and 
treatment of the index condition (i.e. BD).  
 
Methods 
Participants 
Participants were recruited by the Bipolar Disorder Research Network (BDRN) to an on-
going programme of research into the genetic and non-genetic causes of BD. The study has 
UK National Health Service (NHS) Research Ethics Committee approval and local Research 
and Development approval in all participating NHS Trusts/Health Boards. Participants were 
recruited systematically via NHS mental health services, and non-systematically via 
advertisements on the BDRN website, in general practitioner surgeries and local media, and 
patient support organisations (such as Bipolar UK). Participants are included in the BDRN 
study if they meet the following criteria: i) capable of providing written informed consent; ii) 
aged at least 18 years; iii) meet DSM-IV criteria for a major affective disorder; and, iv) due to 
the study’s genetic focus, UK/Ireland White ethnicity. The exclusion criteria are individuals 
who: i) have only experienced affective illness secondary to alcohol or substance abuse, 
medical illness or medication; ii) have a cognitive impairment that affects their ability to 
complete the measures; and, iii) are biologically related to another BDRN participant. After 
complete description of the study to the participants, written informed consent was 
obtained. The present analysis was performed on a subset of BDRN participants with DSM-
IV bipolar I disorder who completed measures of both autistic spectrum and schizotypal 
traits (N=797).  
 
Assessments 
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Lifetime clinical data were compiled by trained research psychologists and psychiatrists 
using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) semi-structured 
interview (Wing et al., 1990), and available psychiatric case notes. Data were combined for 
each participant, and lifetime best-estimate diagnostic and key clinical ratings (such as age 
of illness onset and lifetime presence of psychosis) were made based on pre-specified 
guidelines. Specifically, following SCAN guidelines, the worse episode (‘peak of the disorder’ 
or most severe episode) of each of depression and mania was decided in consultation with 
the participant. In very rare cases where there was discrepancy between the participant’s 
chosen episode and their medical case-notes, a consensus decision was made with the 
clinical team about the worst episode. 
 
Global functioning 
The Global Assessment Scale (GAS) (Endicott et al., 1976) was used to rate global 
functioning during lifetime worst depressive and manic episode separately (GASD and 
GASM, respectively). Scores range 1-100, with higher scores reflecting higher functioning. 
All ratings, including GASD and GASM, were made independently by at least two members 
of the research team and consensus reached. Inter-rater reliability was formally assessed 
using 20 random cases. Mean kappa statistics were 0.85 for DSM–IV diagnoses, and 
between 0.81 and 0.99 for other key clinical categorical variables. Mean intra-class 
correlation coefficients were between 0.91 and 0.97 for key clinical continuous variables, 
including GASD and GASM. 
 
Autism and schizotypal traits 
Autism and schizotypal traits were self-rated using the Autism-Spectrum Quotient (AQ-
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Short) (Hoekstra et al., 2011) and Kings Schizotypy Questionnaire (KSQ) (Jones et al., 2000). 
Participants were administered the KSQ at the end of the clinical interview, and AQ-Short 
was subsequently administered via a questionnaire mail-out.  
 
Autism-Spectrum Quotient (AQ-Short) 
Autistic traits were assessed using an abridged version of the Autism-Spectrum Quotient 
(AQ-Short) (Hoekstra et al., 2011), a 28-item questionnaire that generates a total AQ score 
(range 28-112). Higher scores reflect higher levels of autistic traits. Hoekstra et al have 
suggested an AQ-Short score >65 as a cut-off for clinically significant levels of autistic traits, 
and ≥70 as a further stringent cut-off (Hoekstra et al., 2011). The AQ-Short consisted of five 
subscales as follows: Social skills, routine, switching, imagination, and numbers and 
patterns. The internal consistency in this study is good (Cronbach’s α = 0.80) and is 
comparable to the values reported by Hoekstra et al. (2011), which ranged from .78-.86 
across 4 different samples.  
 
Kings Schizotypy Questionnaire (KSQ) 
Positive schizotypal traits were evaluated using the positive subscale (range 0-45) of the 
Kings Schizotypy Questionnaire (KSQ-Positive) (Jones et al., 2000). A clinical cut-off is not 
available for this scale, but previous research showed that, on average, healthy controls 
score 7, schizophrenia patients score 17, and BD patient score intermediately at about 11 
(Heron et al., 2003). The questionnaire is reliable (Cronbach’s α = 0.81) and valid, correlating 
at .63 with the Schizotypy Traits Questionnaire (Claridge & Broks, 1984). Higher scores 
reflect higher levels of positive schizotypal traits. The KSQ-positive consisted of 5 subscales 
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as follows: Recurrent illusions 1, recurrent illusions 2, magical thinking, paranoid ideation, 
and ideas of reference. The internal consistency of this questionnaire in this study is high 
(Cronbach’s α = 0.903).   
 
Data analysis 
To achieve the first objective, the proportions of participants scoring above the clinically 
significant and stringent AQ-Short thresholds were calculated, with 95% confidence 
intervals (95% CI). The mean KSQ-Positive score in the sample, with 95% CI, was calculated 
for comparison with previous samples reported in the literature.  
 
To address the second objective, we first conducted an individual differences analysis using 
backward linear regression to examine the best predictors of global functioning during 
lifetime worst depressive and manic episode (GASD and GASM, respectively), with AQ-Short 
score, KSQ-Positive score, the AQ-Short x KSQ-Positive interaction term, and all 
demographic and clinical variables included in the model. The backward linear regression 
was constrained such that the AQ-Short score, KSQ-Positive score, and the AQ-Short x KSQ-
Positive interaction term were retained in the final model. However, collinearity diagnostics 
showed multicollinearity violations for KSQ-positive (Variance Inflation Factor =39.97) and 
the interaction term (Variance Inflation Factor =44.59). To remedy this violation, we 
conducted a Principle Component Analysis (PCA) with varimax rotation on the scores 
obtained on the individual subscales of the AQ-short and KSQ-Positive. The analysis 
produced two components: an autism factor (AQ-PC) and a positive schizotypy factor (KSQ-
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Positive-PC; see Supplementary Material for details). The components’ regression 
coefficient scores and their interaction were used in the regression model. 
 
Significant interactions were probed with the Johnson-Neyman method using MODPROBE 
for SPSS (Hayes & Matthes, 2009). This method provides a ‘high-resolution picture’ of the 
interaction by estimating the value(s) of AQ-PC at which KSQ-Positive-PC (or vice versa) has 
a significant effect on global functioning. This is established by identifying the precise 
value(s) along the continuum of one variable for which the regression slopes of the other 
variable are estimated to be significantly different from zero.  
 
Next, K-means cluster analysis was performed to classify participants by level of autistic and 
positive schizotypal traits based on the two components’ regression scores from the PCA 
analysis. This analysis produced four groups: low autistic, low positive schizotypal (LALP); 
low autistic, high positive schizotypal (LAHP); high autistic, low positive schizotypal (HALP); 
and high autistic, high positive schizotypal (HAHP). The group analysis aimed to investigate if 
specific autism-schizotypy trait clustering is associated with different levels of functioning.  
Differences in demographic and lifetime clinical characteristics between these four groups 
were examined using analysis of variance (ANOVA), with post-hoc Bonferroni correction, for 
continuous variables; Kruskal-Wallis tests (with post-hoc Bonferroni-corrected pairwise 
comparisons) for non-normally distributed continuous variables; and chi-squared tests for 
categorical variables.  
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Two separate ANOVAs, with post-hoc Bonferroni corrections, were conducted to examine 
differences between the four groups in global functioning during lifetime worst depressive 
and manic episodes (GASD and GASM, respectively). All demographic and lifetime clinical 
variables were subsequently included as covariates in two separate analyses of covariance 
(ANCOVA) to control for the effect of potential confounders on group differences in GASD 
and GASM scores.  
 
All analyses were undertaken using SPSS (version 22.0), with two-sided p values considered 
significant at p<0.05. 
 
Results 
Expression of Autistic and Positive Schizotypal Traits 
On the AQ-Short, the sample scored a mean of 65.02 (SD=11.51; 95% CI 64.22-65.82). When 
comparing males and females, the males (Mean ± SD= 68.66±10.76) scored significantly 
higher than the females (Mean ± SD=63.79±11.50) (tdf=795 = 5.28, p<.001, Cohen’s d=.44).  
Using the AQ-Short cut-off of >65, 47.2% (95% CI=43.7-50.7%) of the entire sample scored 
positive for clinically significant levels of autistic traits, 60.20% (95% CI=53.43-66.97%) in 
males, and 42.79% (95% CI=38.82-46.75%) in females. When using the more stringent cut-
off (AQ-Short≥70), 36.1% (95% CI=32.8-39.5%) of the entire sample scored at or above this 
cut-off, 50.75% (95% CI=43.83-57.66%) in males, and 31.21% (95% CI=24.80-37.6%) in 
females.  
 
On the KSQ-Positive scale, the sample scored a mean of 11.98 (SD=9.33; 95% CI 11.33-
12.62). There was no significant difference between the males (Mean ± SD=11.37±8.60) and 
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the females (Mean ± SD=12.18±9.56) (tdf=795 = -1.06, p=.290). As noted above, a clinical cut-
off is not available for this scale. However, as a potential cut-off, we used the mean score of 
17 reported for schizophrenia patients (Heron et al., 2003). Using that score, 23.22% (95% 
CI=20.29-26.14) of our sample scored above this cut-off.  
 
Individual differences analysis: Global Functioning in Depression and Mania  
As shown in Table 1, the overall final models of the backward regressions were significant in 
each mood state. In the worst episode of depression (GASD), the final model contained 
seven variables explaining 44.9% of the variance. Four variables were significantly 
associated with poorer global functioning as follows: females, history of psychosis in 
depression, longer illness duration and higher mean number of depressive episodes per 
illness year. In contrast, global functioning was positively associated with the interaction 
term of the autism and positive schizotypy components (i.e., AQ-PC x KSQ-Positive-PC). In 
the worst episode of mania (GASM), the final model contained six variables, explaining 
44.2% of the variance. Poorer global functioning was associated with being older at the time 
of interview and having a history of psychosis in mania. In contrast, better global functioning 
was associated with individuals who attended higher education, and higher scores on the 
autism and positive schizotypy components. The interaction term between the autism and 
positive schizotypy components was non-significant.  
Table 1 about here 
In probing the interactive effect of autism and positive schizotypal traits on GASD, the 
Johnson-Neyman analysis revealed that increasing positive schizotypal traits was associated 
with significantly poorer global functioning in individuals scoring more than .93 SD below 
mean on the AQ factor. This trend was reversed such that positive schizotypal traits were 
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significantly associated with better global functioning in individuals scoring 1.57 SD above 
the mean on the AQ factor. Conversely, increasing autism traits were significantly associated 
with poorer global functioning in individuals scoring .33 SD below the mean on the positive 
schizotypy factor. This trend was reversed such autism traits were associated with better 
global functioning in individuals scoring 2.68 SD above the mean the positive schizotypy 
factor (see Figure 1).   
Figure 1 about here 
Classification into Groups, and Group Characteristics 
Based on participants’ levels of autistic and positive schizotypal traits, K means cluster 
analysis identified the following four groups: low autistic, low positive schizotypal (LALP; 
N=282, 35.38%), low autistic, high positive schizotypal (LAHP; N=118, 14.81%), high autistic, 
low positive schizotypal (HALP; (N=286, 35.88%), and high autistic, high positive schizotypal 
(HAHP; N=111, 13.93%). Comparisons of demographic and lifetime clinical characteristics 
between these groups are summarised in Table 2. There were significant differences 
between the groups for age at interview, gender distribution, lifetime highest level of 
education, mean number of depressive and manic episodes, and history of psychosis in 
depression.  
Table 2 about here 
Comparison of Global Functioning Between Groups 
There were significant differences between the groups in global functioning in both mood 
states (GASD: F(3,715)=4.35, p=0.005, R2=0.018; GASM: F(3,776)=5.43, p=0.001, R2=0.021). 
In the worst episode of depression, the LAHP group had worse functioning than the LALP 
group (GASD mean difference=3.81, p=0.007, Cohen’s d= .36) (see Figure 2A). In the worst 
episode of mania, the HAHP group had better functioning than the LALP group (GASM mean 
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difference=4.66, p=0.001, Cohen’s d= .43), the LAHP group (GASM mean difference=4.15, 
p=0.031, Cohen’s d= .37), and the HALP group (GASM mean difference=4.69, p=0.001, 
Cohen’s d= .43) (see Figure 2B). When adjusting for demographic and lifetime clinical 
variables (see Table 2) the differences among the groups became non-significant 
(F(3,597)=1.88, p=.131) in the GASD model (N=611), but remained significant 
(F(3,627)=6.71, p<0.001, R2=0.031) in the GASM model (N=641). In the adjusted GASM 
model, the functioning of the HAHP group was significantly better than the LALP group 
(mean difference=4.82, p<0.001, Cohen’s d= .52), LAHP group (mean difference=4.83, 
p=0.001, Cohen’s d= .46) and HALP group (mean difference=3.72, p=0.006, Cohen’s d= .39). 
Note, the sample sizes of the adjusted models are smaller due to missing data. 
Figure 2 about here 
Discussion 
This study sought to assess the expression of autistic and positive schizotypal traits in a 
large, well-characterised, adult sample of BD (N=797), and their concurrent effect on global 
functioning. Approximately, half of the sample exhibited clinically significant levels of 
autistic traits, and over a third on applying a more conservative cut-off. This is consistent 
with the single previous study of autistic-like traits conducted in an adult BD sample, in 
which half of the participants demonstrated high levels of autistic-like traits (Matsuo et al., 
2015). These results also support phenomenological commonalities reported between ASD 
and BD (Vannucchi et al., 2014), and speculatively genetic overlaps (Cross-Disorder Group of 
the Psychiatric Genomics, 2013; Ellis, Panitch, West, & Arking, 2016). However, interpretive 
caution is required, as these overlaps do not confirm shared aetiology. 
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It is worth noting that the mean scores of the autistic traits of the males and females in our 
sample were intermediate to the mean scores reported by Hoekstra et al (2015) for their 
English controls and Asperger Syndrome cohorts. Specifically, the mean scores of the males 
and females in our sample were respectively higher than the means of the males (N=737; 
Mean difference = 8.93; Cohen’s d=.90) and females (N= 1,101; Mean difference = 7.79; 
Cohen’s d=.76) of their English controls cohort, and lower than the means of the males 
(N=56; Mean difference = -19.10; Cohen’s d=-1.67) and females (N=117; Mean difference = 
27.70; Cohen’s d=-2.40) of their English Asperger Syndrome cohort.  
 
The observed mean KSQ-Positive score in the overall sample (mean=11.98) was consistent 
with findings previously reported in BD (Heron et al., 2003). Heron et al further described 
that the expression of positive schizotypal traits in BD (mean=11.48) is less than that 
observed in a similarly ascertained schizophrenia group (mean=17.37), yet greater than in 
healthy controls (mean=7.05). Similarly, Mahon et al showed that individuals with BD (N=55) 
had elevated rates of schizotypy compared to healthy controls, as measured by the 
Schizotypal Personality Questionnaire (Mahon et al., 2013). Participants’ unaffected siblings 
scored intermediately, suggesting that schizotypy is a dimensional trait that contributes to 
the genetic risk for BD (Mahon et al., 2013).  
 
This study’s second objective was to examine the effect of co-occurring autistic and positive 
schizotypal traits on global functioning in BD. Generally, both the individual differences (i.e., 
regressions) and group analyses provided evidence that both autistic and positive 
schizotypal traits were associated with better global functioning, such that their effects 
were greatest when both traits were high rather when both were low. Specifically, during 
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the worst episode of mania, the individual differences analysis showed that both autism 
traits and positive schizotypal traits independently contributed to increased global 
functioning. This was consistent with the results from the group analysis, which showed that 
the functioning of the high autism, high positive schizotypal group were significantly better 
than the other groups during the worst episode of mania even after controlling for potential 
confounders. During the worst episode of depression, individual differences analysis 
showed that autistic and positive schizotypal traits were interactively associated with 
increased global functioning. However, the group analysis revealed no differences among 
the groups after adjusting for confounders. It is possible that the individual differences 
analysis is a more sensitive approach than group-based analysis, particularly as it allows us 
to explore interactions across the entire rage of the autism and positive schizotypal traits. 
Collectively, these findings suggest that high levels of co-occurring autistic and positive 
schizotypal traits may be associated with a normalising effect on global functioning, and are 
consistent with the improvement effect of these co-occurring traits in the general 
population on tasks tapping perspective-taking (Abu-Akel et al., 2015) and attentional 
abilities (Abu-Akel, Apperly, Wood, Hansen, & Mevorach, 2016).  
 
However, the mechanism by which this takes place is currently unknown, and thus should 
be the focus of future research. It is worth noting however that the pattern of the 
interactive effect of autistic and schizotypal traits on global functioning during the worst 
depressive episode suggests that the effect of the expression of one condition depends on 
the relative expression of the other condition, and that these dimension traits may be 
interacting in a compensatory manner to improve global functioning. We conjecture that 
this interactive effect on global functioning is likely driven by more basic functions/abilities 
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such as attention and mentalising abilities where autism and positive symptoms tend to 
exert opposite effect on naturally interacting genetic/biological systems subserving these 
abilities (Abu-Akel, Apperly, Wood, & Hansen, 2016). If verified, this would be consistent 
with recent genetic evidence suggesting either shared aetiology or compensatory changes 
across these neuropsychiatric conditions (Ellis et al., 2016), and with the apparent 
susceptibility of global functioning to gene-dosage effects of shared autism and 
schizophrenia risk loci (Abu-Akel, Wood, Hansen, & Apperly, 2016; Stefansson et al., 2014). 
Yet, the precise genetic mechanisms underlying these effects remain elusive that need to be 
addressed in future work.  
 
Taken together, there appears to be a pattern whereby co-occurring high levels of both 
traits are associated with better global functioning. However, the large sample size allowed 
the detection of small but statistically significant differences in global functioning between 
groups that are of only marginal clinical significance. The difference observed in global 
functioning in the worst episode of mania between the high autistic, high positive 
schizotypal group compared to the other three groups translates to a one decile change on 
the GAS, such that the average global functioning observed in the high autistic, high positive 
schizotypal trait group equates to ‘major impairment in several areas’, compared to being 
‘unable to function in almost all areas’. Therefore, although the association between high 
levels of both traits and better global functioning is robust – withstanding a large number of 
covariates – the level of global functioning observed in the high autistic, high positive 
schizotypal group remains markedly impaired.  
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Nonetheless, as the relative expression of both traits appears to have measurable 
consequences on functioning and illness outcomes, screening for both autistic and 
schizotypal traits in BD patients, may be of significant value to understanding the 
heterogeneity of BD. In addition, the robustness of the expression of both autistic and 
schizotypal traits suggest that screening for both traits may be of theoretical and clinical 
importance. Specifically, the high level of expressions of autistic traits in over a third of the 
sample underscores the importance of routinely assessing autism in BD patients, which may 
contribute to improved diagnostic practices in this population. To this end, the 
administration of standard diagnostic schedules is required. Finally, further investigations of 
the co-expression of autism and schizotypy/schizophrenia in BD may yield important 
insights about the inter-relationship of these neuropsychiatric conditions. This is warranted 
given recent evidence for this inter-relationship from genetic (Ellis et al., 2016; Goes et al., 
2016), neurodevelopmental (O'Shea & McInnis, 2016), neurobiological as well as 
psychopathological studies (Abdolmaleky, Zhou, & Thiagalingam, 2015; Panaccione et al., 
2013; Sani et al., 2012; Skokauskas & Frodl, 2015). This also can help explain performance in 
other domains relevant to global functioning such as mentalising, which has been shown to 
be affected in all three conditions (Bora, Bartholomeusz, & Pantelis, 2016). 
 
The findings must be interpreted in light of several limitations. The findings are likely to be 
affected by volunteer bias as the majority of the sample was recruited non-systematically. 
Individuals who volunteered to participate in research may systematically differ in their 
level of functioning, and other characteristics, compared to the overall BD population. For 
example, with a male to female ratio of 1:3, the sample does not reflect the gender 
distribution in the BD population whereby lifetime rates of BD I are higher in males 
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(Merikangas et al., 2011). The sample was further restricted to UK White adults, therefore 
the results may not be generalizable to other ethnicities. Furthermore, the study used two 
self-rated questionnaires to measure autistic and schizotypal traits; due to the subjective 
nature of these measures, the levels of traits reported were open to response bias and 
therefore may be inaccurate. In addition, the GAS has widely acknowledged limitations such 
as raters’ subjective bias and conflation of symptom severity (Gold, 2014). Clinical data were 
also collected retrospectively by interview, hence vulnerable to recall bias, although the 
interview data were supported by contemporaneous psychiatric case-note data where 
possible. Finally, determining the peak of the disorder might entail some uncertainties, as 
some individuals might have not yet experienced their worst lifetime episode. Therefore, 
assessing the effects of these traits during euthymia is an important next step for future 
research, which would enable us to assess how these trait dimensions affect functioning 
outside mood episodes. This is particularly important in light of recent research reporting 
cognitive (Buoli, Caldiroli, Caletti, Zugno, & Altamura, 2014) and socio-cognitive (Bora et al., 
2016) impairment during euthymia.  
 
In conclusion, this study is the first to assess the expression of autistic and schizotypal traits 
in a large sample of adults with BD. The high frequency of autistic traits observed 
emphasises that a significant proportion of BD patients may benefit from screening for 
these traits, and potentially more individualised management. Furthermore, this is the first 
study to concurrently assess both autistic and schizotypal traits in BD I, hence the first to 
report that the interaction between these traits is associated with an outcome of clinical 
value, i.e., better global functioning. These findings require replication in independent 
samples, including samples with primary psychotic disorders (e.g. schizophrenia). Moreover, 
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the association of the interaction of autistic and schizotypal traits with improved functioning 
may have potential implications for investigating compensatory changes or mechanisms in 
BD I. Future work should focus on investigating the biological and/or psychosocial 
mechanisms underlying better global functioning in those with high levels of both autistic 
and schizotypal traits.  
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Table 1. Variables associated with global functioning during lifetime worst 
depressive episode (GASD) and manic episode (GASM) in adults with bipolar I 
disorder. 
 
Outcome Variables β SE t p Modelc 
p R2 
GASDa Female -2.09 .727 -2.87 0.004 <0.001 
 
0.449 
History of psychosis in depression -14.39 .718 -20.05 <0.001 
Longer illness duration -0.17 .026 -6.35 <0.001 
Higher mean number of depressive 
episodes/illness year 
-1.12 .530 -2.11 0.035 
AQ-PC d -0.307 .305 -1.01 0.314 
KSQ-Positive-PC d 0.049 .324 0.15 0.880 
AQ-PC x KSQ-Positive-PC 0.771 .330 2.33 0.020 
GASMb Older age at interview -0.09 .031 -2.97 0.003 <0.001 0.422 
History of psychosis in mania -15.17 .739 -20.52 <0.001 
Higher education 1.73 .683 2.53 0.012 
AQ-PC d 1.100 .335 3.28 0.001 
KSQ-Positive-PC d 1.22 .358 3.42 0.001 
AQ-PC x KSQ-Positive-PC 0.130 .336 0.35 0.724 
 
a GASD, Global Assessment Scale score during lifetime worst Depressive episode. 
b GASM, Global Assessment Scale score during lifetime worst Manic episode. 
c Final models are the results of backward regressions. Initial models included all 
demographic (age at interview, gender, marital history, lifetime highest level of education, 
recruitment method) and clinical variables (illness duration, history of psychosis in 
depression and mania, and mean number of depressive and manic episodes per illness year) 
as predictors, in addition to scores on the AQ-PC, the KSQ-Positive-PC, and their interaction 
(i.e., AQ-PC x KSQ-Positive-PC). 
d AQ-PC and KSQ-Positive-PC are respectively the autism and positive schizotypy 
components’ regression scores per the Principle Component Analysis (see Supplementary 
Material).
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Table 2. Demographic and clinical characteristics of groups with high/low levels of autistic and positive schizotypal traits, in an adult sample of bipolar disorder. 
 
Characteristic 
 
Overall sample 
(N=797) 
Group  
Group Differences LALP 
(N=282) 
LAHP 
(N=118) 
HALP 
(N=286) 
HAHP  
(N=111) 
Demographic variables a Mean SD Mean SD Mean SD Mean SD Mean SD F df p 
Age at interview (years) b 49.09 11.30 50.16 11.95 45.92 10.83 50.63 10.90 45.80 9.75 9.13 3 <0.001 
 N % N % N % N % N % χ2 df p 
Female c 596  74.80 220 78.00 100 84.70 199 69.6 77 69.4 13.60 3 0.004 
Married/lived as married d 673 85.20 239 85.4 100 84.70 239 84.5 95 87.20 0.48 3 0.92 
Undergraduate degree or higher e 365  
 
47.70 148 54.80 54 47.80 120 43.20 43 41.00 9.69 3 0.021 
Non-systematically recruited f  615 77.8 224 80.30 89 76.10 209 73.60 93 84.50 7.02 3 0.071 
Clinical variables a Mean SD Mean SD Mean SD Mean SD Mean SD F df p 
Illness duration (years) g 25.34  12.14 24.61 13.05 24.38 11.15 26.35 12.02 25.52 10.97 1.20 3 0.31 
 Median IQR Median IQR Median IQR Median IQR Median IQR KW χ2 df p 
Mean number of depressive 
episodes per illness year h 
0.35 0.48 0.26 0.42 0.40 0.47 0.33 
 
0.48 0.54 0.58 19.92 3 <0.001 
Mean number of manic episodes 
per illness year  i 
0.29 0.37 0.23 0.34 0.33 0.42 0.28 0.33 0.43 0.50 18.96 3 <0.001 
 N % N % N % N % N % χ2 df p 
History of psychosis in depression j 184  
 
25.10 50 18.90 38 35.50 58 22.30 38 38.00 21.56 3 <0.001 
History of psychosis in mania k 535 
 
68.90 189 68.70 81 72.30 191 68.00 74 68.50 0.74 3 0.83 
LA, Low Autistic traits; HA, High Autistic traits; LP, Low Positive schizotypal traits; HP, High Positive schizotypal traits.  
SD= Standard Deviation; IQR= Interquartile Range; KW χ2= Kruskal Wallis χ2; MD= Mean Difference. 
a Ns vary due to missing data: d (N=790); e (N=766); f (N=790); g (N=765); h (N=708); i (N=740); j (N=732); k (N=776). 
b LALP>LAHP, MD=4.25, p=0.003; LALP>HAHP, MD=4.36, p=0.003; HALP>LAHP, MD=4.17, p=0.001; HALP>HAHP, MD=4.83, p=0.001. It is worth noting that previous 
research reported no significant association in the expression of autism traits and age of participants (Hoekstra, Bartels, Cath, & Boomsma, 2008) 
c LAHP>HALP, χ2=9.96, p=0.002; LAHP>HAHP, χ2=7.67, p=0.006.  
e None of the pairwise comparisons survived Bonferroni correction. 
h LALP<LAHP, χ2=10.08, p=0.009; LALP<HAHP, χ2=18.30, p<0.001; HALP<HAHP, χ2=9.18, p=0.015.  
i LALP<HAHP, χ2=19.89, p<0.001; LALP<LAHP, χ2=10.53, p=0.007.  
j LALP<LAHP, χ2=11.66, p<0.001; LALP<HAHP, χ2=14.49, p<0.001; HALP<HAHP, χ2=6.83, p=0.009; LAHP>HALP, χ2=9.07, p=0.003. 
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Figure 1. Visualisation of the interacitve effect of autism and positive schizotypal traits on 
global functioning during worst depressive episode. Figure 1A shows that AQ traits are 
significantly associated with poorer global functioning when positive schizotypal traits 
scores are .33 SD or more below the mean  (at SD= -.33; β(se)=-.63(.32), t=-1.96, p=.05), and 
significantly associated with better global functioning at 2.68 SD or more above the mean 
(at SD=2.68; β(se)=1.83(.93), t=1.96, p=.05). Figure 1B shows that positive schizotypal traits 
are significantly associated with poorer global functioning when autism traits scores are .93 
SD or more below the mean (at SD=-.93; β(se)=-.88(.45), t=-1.96, p=.05), and significantly 
associated with better global functioning at 1.57 SD or more above the mean (at SD=1.57; 
β(se)=1.16(.59), t=1.96, p=.05).  
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Figure 2. Global functioning as a function of autistic and positive schizotypal traits in adults 
with bipolar I disorder. Figure 2A displays the global functioning scores of the groups in the 
worst depressive episode. Analysis is based on data from 719 participants due to missing 
data. Figure 2B displays the global functioning scores of the groups in the worst manic 
episode. Analysis is based on data from 780 participants due to missing data. LALP=low 
autistic, low positive schizotypal. LAHP=low autistic, high positive schizotypal. HALP=high 
autistic, low positive schizotypal. HAHP=high autistic, high positive schizotypal. Error bars 
denote standard error of the mean. *=p<0.05; **=p<.01. 
25
30
35
40
45
LALP (N=254) LAHP (N=109) HALP (N=252) HAHP (N=104)
M
ea
n 
gl
ob
al
 fu
nc
tio
ni
ng
 sc
or
e 
(G
AS
) 
Group 
Figure 2A: Worst depressive episode ** 
25
30
35
40
45
LALP (N=277) LAHP (N=115) HALP (N=279) HAHP (N=109)
M
ea
n 
gl
ob
al
 fu
nc
tio
ni
ng
 sc
or
e 
(G
AS
) 
Group 
Figure 2B: Worst manic episode 
** 
* ** 
  
  28 
Supplementary Material 
 
Principle Component Analysis  
Constraining the backward elimination regression model by the concurrent inclusion of the AQ-
Short, KSQ-Positive and their interaction term in the final model resulted in a multicolinearity 
violation. To remedy this situation, we conducted a Principle Component Analysis (PCA) on the 
scores of the five subscales of the AQ-Short (Hoekstra et al., 2011) (i.e., Social Skills, Routine, 
Switching, Imagination, and Numbers and Patterns) and the five subscales of the KSQ-Positive (Jones 
et al., 2000) (i.e., Recurrent Illusions 1, Recurrent Illusions 2, Magical Thinking, Paranoid Ideation, 
Ideas of Reference) following Dinsdale and colleagues (Dinsdale, Hurd, Wakabayashi, Elliot, & Crespi, 
2013). Here, the PCA was conducted with a varimax rotation to maximize orthogonality and Kaiser 
Normalization. Moreover, variables with high (≥ 0.4) communalities (i.e., the proportion of each 
variable's variance that can be explained by the principal components) were retained. This resulted in 
the exclusion of the AQ Numbers and Patterns subscale, which had a communality score of only 0.190. 
The communalities of the remaining 9 subscales ranged from 0.438 – 0.768.  
 
The PCA analysis produced two factors with eigenvalues ≥ 1, cumulatively explaining 58.18% of the 
variance. The first component was the positive schizotypy component (KSQ-Positive-PC), which 
explained 37.67% of the variance, and the second is the AQ component (AQ-PC), which explained 
20.51%. Table 1S shows the loadings of the two principal components across the AQ-Short and KSQ-
Positive subscales. 
 
Table 1S. The principle components’ loadings across the AQ-Short and the KSQ-positive subscales 
Measure Subscale KSQ-Positive-PC 
(eigenvalue = 3.77; 
variance = 37.67%;) 
AQ-PC 
(eigenvalue = 2.05; 
variance = 20.51%) 
KSQ-Positive Recurrent illusions 2 .870  
 Ideas of reference .866  
 Recurrent illusions 1 .816  
 Magical thinking .769  
 Paranoid ideation .760  
AQ-Short Routine  .768 
 Switching  .760 
 Social Skills  .750 
 Imaginations  .618 
PCA statistics 
Kaiser-Meyer-Olkin measure of sampling 
adequacy  
.824 
Bartlett's test of sphericity χ2(df=45) = 3141.03, p<.001 
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